一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.
Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们证明 CTR 可提供多种无创临床病理信息。CTR 超过 75% 是与不良预后相关的因素,在为早期 NSCLC 患者制定治疗方案时应予以考虑。
计算机断层扫描上的磨玻璃影(GGO)与早期非小细胞肺癌(NSCLC)患者的预后相关。然而,GGO预后价值的风险分层存在争议。我们旨在基于实性成分与肿瘤直径比值(CTR)评估早期NSCLC的临床病理特征,进行多方位分析,并据此进行预后分层。
我们回顾性研究了944例临床IA期NSCLC患者,这些患者在2018年8月至2020年1月期间接受了根治性意向的肺切除术。测量了CTR,并据此将患者分为六组(1组,0%;2组,0-25%;3组,25-50%;4组,50-75%;5组,75-100%;6组,100%)。
病理淋巴结升期分别见于1.8%(第4组)、9.0%(第5组)和17.4%(第6组)。随着CTR增加,高等级TIL(肿瘤浸润淋巴细胞)的患者比例呈下降趋势。在腺癌患者的亚型分析中,所有以微乳头型为主的患者均位于CTR > 50%组,而以实性型为主的患者大多位于第6组(47/50,94%)。多因素分析显示,无论肿瘤大小如何,CTR 75-100%(风险比[HR],3.85;95%置信区间[CI],1.58-9.36)和CTR 100%(HR,5.58;95% CI,2.45-12.72)均为DFS的独立预后因素。
Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly.
We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0-25%; 3, 25-50%; 4, 50-75%; 5, 75-100%; and 6, 100%).
Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75-100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58-9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45-12.72) were independent prognostic factors for DFS, regardless of tumor size.
We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。